



TriClip™  
Transcatheter Edge-to-Edge Repair

# EXPERIENCE MATTERS

Information contained herein for DISTRIBUTION  
in Europe, Middle East, and Africa ONLY.





## TRICLIP™ TEER TOGETHER WE EMPOWER EACH OTHER TO TREAT PATIENTS WITH OUTSTANDING PERFORMANCE IN TEER


With Abbott's help, you've **transformed more than 10,000<sup>1</sup> lives** with TriClip™ TEER, including Cruz's, and that number is growing every day.

“Now I am fine. Because my heart is doing well. We keep living life the best we can... A normal life.”

Cruz, TR patient treated in 2018 as part of the TRIULIMINATE™ EFS Trial.\*

\*This testimonial relates an account of an individual's response to the treatment. This patient's account is genuine, typical, and documented. However, it does not provide any indication, guide, warranty, or guarantee as to the response other persons may have to the treatment. Responses to the treatment discusses can and do vary and are specific to the individual patient.

## TRICLIP™ TEER THERAPY IS PROVEN IN THE LARGEST BODY OF REAL-WORLD EVIDENCE TO DATE<sup>2,3</sup>



**91%** Procedural success rate<sup>4</sup>

**97.5%** Freedom from MAEs at 30 days<sup>4</sup>

**77%**

NYHA class I/II at 1 year from 21% at baseline<sup>2</sup>

**+21 points**

Improvement in KCCQ-OS at 1 year<sup>2</sup>

Information contained herein for DISTRIBUTION in Europe, Middle East, and Africa ONLY.



# TRICLIP™ TEER

## THE FIRST CHOICE TO RESTORE THE TRICUSPID VALVE, PAVING THE WAY IN TRANSCATHETER TRICUSPID INTERVENTIONS



2015

2017

2019

2020

2021

2023

TRILUMINATE™ EFS TRIAL STARTS  
85 Patients

TRILUMINATE™ PIVOTAL TRIAL STARTS  
886 Patients

LAUNCH OF TRICLIP™ TEER SYSTEM NT & XT



TRILUMINATE™ EFS  
Full cohort  
1-year results

BRIGHT STUDY STARTS  
511 Patients

LAUNCH OF TRICLIP™ G4 TEER SYSTEM



BRIGHT STUDY  
Initial cohort  
30-day results

TRILUMINATE™ PIVOTAL TRIAL  
Full randomised and single-arm  
1-year results

TRILUMINATE™ EFS  
Full cohort  
3-year results

ADDRESSING THE FORGOTTEN VALVE<sup>7</sup>

PROVEN SAFETY AND EFFICACY<sup>5</sup>

FIRST T-TEER COMMERCIALY AVAILABLE<sup>1</sup>


BROAD RANGE OF ANATOMIES EFFECTIVELY TREATED<sup>4</sup>

FIRST RCT IN TR DISEASE<sup>6</sup>

TRICLIP™ TEER  
**10,000<sup>1</sup> LIVES CHANGED**

## TRILUMINATE™ PIVOTAL - 1-YEAR RESULTS<sup>6</sup>

Prospective, randomized, multi-center, controlled clinical trial to compare TriClip™ TEER System vs. medical therapy



IMPROVEMENT IN KCCQ-OS IN 49.7% OF PATIENTS



TR MODERATE OR LESS



DEVICE THROMBUS OR EMBOLIZATION; NONELECTIVE CV SURGERY

“What this trial has shown is that we have an incredibly effective and safe therapy that improves quality of life. This is what patients want.”

Dr. P. Sorajja  
TRILUMINATE™ Pivotal Trial - Principal Investigator\*

\*The testimonial does not provide any indication, guide, warranty or guarantee as to the response patients may have to the treatment or effectiveness of the product or therapy in discussion. Opinions about the treatment discussed can and do vary and are specific to the individual's experience and might not be representative of others.

Information contained herein for DISTRIBUTION in Europe, Middle East, and Africa ONLY.



## TRICLIP™ TEER EXPERIENCE MATTERS



**10,000+**  
patients treated since 2017<sup>1</sup>



**50+**  
countries worldwide<sup>1</sup>



**1,300+**  
patients studied in Abbott-sponsored  
trials, including 3 landmark studies<sup>1</sup>

## THANK YOU FOR THE PARTNERSHIP IN THIS JOURNEY



Information contained herein for DISTRIBUTION in Europe, Middle East, and Africa ONLY.



Visit CONNEXT by Advanced Heart Therapies to find out more about TriClip™ TEER and access **next-level cardiovascular educational content** tailored just for you

CE, conformité européenne; CV, cardiovascular; EFS, early feasibility study; FDA, food and drug administration; KCCQ-OS, Kansas City Cardiomyopathy Questionnaire Overall Score; Lab, laboratory; MAE, major adverse event; mod, moderate; NYHA, New York Heart Association; RCT, randomized controlled trial; TR, tricuspid regurgitation; TEER, transcatheter edge-to-edge repair; T-TEER, tricuspid transcatheter edge-to-edge repair; vs, versus.

**REFERENCES:** 1. Data on file at Abbott. 2. Lurz P., et al. Real-world outcomes from tricuspid edge-to-edge repair: Initial 1 year outcomes from the bRIGHT trial. Presented at PCR London Valves November 27–29, 2022. 3. ClinicalTrials.gov. Find a Study. Accessed November 12, 2021. <https://clinicaltrials.gov/ct2/results?cond=tricuspid+regurgitation&term=transcatheter&cntry=&state=&city=&dist=> 4. Lurz P., et al. Short-term outcomes of tricuspid edge-to-edge repair in clinical practice. *J Am Coll Cardiol.* 2023; 82:281–291. doi: 10.1016/j.jacc.2023.05.008. 5. Nickenig G., et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. *Lancet.* 2019; 394: 2002–2011. doi: 10.1016/S0140-6736(19)32600-5. 6. Sorajja P., et al. Transcatheter repair for patients with tricuspid regurgitation. *N Engl J Med.* 2023; 388:1833–1842. doi: 10.1056/NEJMoa2300525. 7. Nickenig G., et al. Transcatheter Treatment of Severe Tricuspid Regurgitation with Edge-to-Edge: MitraClip Technique. *Circulation.* 2017; 10.1161/CIRCULATIONAHA.116.024848.

CAUTION: Product(s) intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at [vascular.eifu.abbott](http://vascular.eifu.abbott) or at [medical.abbott/manuals](http://medical.abbott/manuals) for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events. Information contained herein for DISTRIBUTION in Europe, Middle East, and Africa ONLY. Always check the regulatory status of the device in your region. Illustrations are artist's representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.

Abbott Vascular International BVBA  
Park Lane, Culliganlaan 2B, 1831 Diegem, Belgium, Tel: 32 2 714 14 11  
™ indicates a trademark of the Abbott Group of Companies.  
[www.my-connext.com](http://www.my-connext.com)  
©2024 Abbott. All rights reserved. 9-EH-1-14947-01 02-2024

